Introduction
Cardiac fibrosis is one of the most common manifestations of post-infarct cardiac remodelling. It is characterized by fibroblast over-proliferation and interstitial collagen deposition. In response to myocardium infarction, the dead myocardium is replaced with fibrotic scar tissues formed by fibroblasts and progressively loses contractile function, which ultimately leads to heart failure (Kong et al., 2014) .
Statins, inhibitors of hydroxymethylglutaryl CoA reductase, restrict cholesterol biosynthesis and have been widely used to treat hypercholesterolemia by lowering total and LDL cholesterol levels (Olyaei et al., 2011) . Apart from lipidlowering, other effects on inflammation and cancer confirm the pleiotropic regulation of cell homeostasis by statins (Desai et al., 2013) . For instance, statins have been demonstrated to induce apoptosis of lymphoma cells by stimulating the p38 pathway (Qi et al., 2013) . Also, statins inhibited proliferation of cancer cells and human airway smooth muscle cells (Takeda et al., 2006; Sanchez et al., 2008) . Moreover, the heart-protective effect of statins has been reported. Rosuvastatin improved heart function in patients suffering from congestive heart failure (CHF) due to ischaemia heart disease (Cleland et al., 2009) . Simvastatin attenuated the CHFinduced atrial structural remodelling and atrial fibrillation promotion in dogs, and its mechanism may be due to statin-induced inhibition of profibrotic atrial fibroblast responses and attenuation of left ventricular dysfunction (Shiroshita-Takeshita et al., 2007) . However, intensive investigations need to be carried out to elucidate the role of statins in mediating the development of cardiac fibrosis.
The TGF-β receptor III (TGFBR3) is an 851-amino-acid transmembrane proteoglycan that is involved in cellular homeostasis, differentiation, proliferation and apoptosis. In some cases, TGFBR3 binds to TGF-β and activates the downstream Smad signalling pathway (Esparza-Lopez et al., 2001) . Recently, we have demonstrated that TGFBR3 functioned as an inhibitor of the TGF-β1/TGF-β2 receptor complex and TGF-β1 expression (Chu et al., 2011) , and we further identified TGFBR3 as a key anti-fibrosis factor via its inhibition of TGF-β1 signalling (Liang et al., 2012) . Here we studied whether TGFBR3 participated in the regulation of cardiac fibrosis by statins. Our data have disclosed a novel mechanism by which simvastatin restricted post-infarct cardiac fibrosis by up-regulating TGFBR3, thereby suppressing ERK1/2 and JNK-dependent fibroblast activity and collagen production.
Methods

Mouse models of myocardial infarction (MI)
All animal care and experimental protocols were in accordance with the Institutional Animal Care, which was approved by the Ethics Committee of Harbin Medical University, China. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals McGrath et al., 2010) . A total of 70 animals were used in the experiments described here.
Male Kunming mice weighing 20-25 g were housed in the environment at a temperature of 20°C with a 12/12 h light/dark cycle. Mice were pretreated with simvastatin (0.5 mg·g −1 ·day −1 ; Sigma-Aldrich Co., LLC, St. Louis, MO, USA) via an intragastric tube for 7 days. Mice were anaesthetized with pentobarbital sodium (40 mg·kg −1 , i.p.), the skin of the chest was shaved and disinfected. The mice were intubated and ventilated with an artificial respiration machine (UGO Basile S.R.L. Biological Research Apparatus, Ugo Basile, Milan, Italy). An incision was performed through the fourth intercos- These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http:// www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 ( a,b Alexander et al., 2013a,b) .
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tal space and the heart was exposed. The left anterior descending coronary (LAD) artery was ligated with 7/0 silk thread. One, 7 or 28 days later, the mice were killed (sodium pentobarbitone, 40 mg kg −1 and xylazine, 12.5 mg kg −1 , i.p.). and the heart dissected for ischaemia zone, border zone and nonischaemia zone. For control mice, a suture was passed through the myocardium around the LAD artery without ligation.
In vivo lentivirus carrying shRNA for TβRIII infection
The lentivirus-mediated shRNA for TGFBR3 (Lenti-shTR3) (5′ CACC GGGA GGTT CACA TCCT AAAC GAAT TTAG GATG TGAA CCTCCC3′) and the lentivirus carrying scrambled shRNA (Lenti-shNC) (5′GTTC TCCG AACG TGTC ACGT3′) as negative control were synthesized by Invitrogen (Shanghai, China). Briefly, mice were anaesthetized, a thoracotomy was performed through the fourth intercostal space. The ascending aortic artery and the main pulmonary artery were clamped. The lentivirus was injected (2.5 × 10E7 TU·mL −1 at volume of 100 μL) through the tip of the heart into the left ventricular cavity. The arteries were occluded for 10 s after lentivirus injection. Treatment with simvastatin was started 7 days after lentivirus injection. After treatment, GFP fluorescence in cryosections of the hearts injected with lentivirus was measured by laser scanning confocal microscopy (FV300; Olympus Medical System, Tokyo, Japan).
Isolation of cardiac fibroblasts
The hearts of neonatal Kunming mice (1-3 days old) were excised and cut into small pieces as described previously . Cardiac fibroblasts were isolated using a 0.25% solution of trypsin and were cultured in 6-well plates containing DMEM (HyClone, Logan, UT, USA) with 10% FBS (HyClone) at 37°C in 5% CO2, 95% air for 48 h before experiments.
Drug administration and transfection of cardiac fibroblasts
Simvastatin was dissolved in DMSO and cells were treated with simvastatin at 1, 5 or 10 μM (final concentration of DMSO was 1%). To induce cell fibrosis, 20% FBS was added to DMEM when cardiac fibroblasts were cultured (Chu et al., 2011) .
Targeting siRNAs and the negative control siRNA were purchased from GenePharma (Shanghai, China). The target sequence of TGFBR3 was sense, 5′ GGGA GGUU CACA UCCU AAATT3′, and antisense, 5′ UUUA GGAU GUGA ACCU CCCTT3′. The target sequence of GAIP-interacting protein C-terminus (GIPC) was sense: 5′ GCAG UGUG AUUG ACCA CAUTT3′, and antisense: 5′AUGU GGUC AAUC ACAC UGCTT3′. Pc-DNA3.1-mTGFBR3 plasmid (GeneChem Co., Ltd, Shanghai, China) and pc-DNA3.1-plasmid (GeneChem Co., Ltd) as an empty vector were all transfected with X-tremeGENE siRNA transfection reagent (Roche Molecular Biochemicals, Mannheim, Germany) for 48 h.
Transmission electron microscopy
Briefly, the samples were fixed in phosphate-buffered 2.5% glutaraldehyde (pH 7.4) at 4°C overnight and immersion postfixed in 0.1 M cacodylate buffer with 1% osmium tetroxide for 1 h . Then samples were dehydrated through a graded ethanol series, embedded in Epon medium and dissected into 60-70 nm sections. Sections were stained with uranyl acetate and lead citrate and were observed with a JEOL 1200 electron microscope (JEOL Ltd, Tokyo, Japan).
Masson staining
Hearts were sectioned and immersed in 10% neutral buffered formalin for 24 h, then stained with Masson's Trichrome (Accustain HT15; Sigma-Aldrich, St. Louis, MO, USA). The extent of collagen deposition was calculated with image analysis software (Image-Pro Plus v4.0; Meida Cybernetics, Bethesda, MD, USA) as previously described .
Measurement of cell viability
Cells were seeded into a 96-well microplate at 10 000 cells per well in 100 μL of medium and treated as described. Cells were incubated with 10 μL MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] solution (SigmaAldrich) (0.5 mg·mL −1 ) for 4 h. Each well received 100 μL of DMSO to dissolve the formazan, and the plate was shaken for 10 min. The absorbance for each well was measured at 490 nm using a microplate spectrophotometer (Tecan Austria GmbH, Untersbergstrasse, Austria).
Measurement of collagen content
A Sircol Collagen Assay kit (Biocolor Ltd., Northern Ireland, UK) was used to determine the total collagen content. Briefly, 0.05 M Tris buffer (pH 7.5) was used to lyse cells, and 1 mL of Sircol Dye reagent was used to stain the lysate (100 mL). Contents were mixed for 30 min and centrifuged for 10 min (at >10 000× g) to pellet the bound dye. Each tube received 1 mL of the alkali reagent to dissolve the bound dye, and the absorbance value was read at 540 nm. Collagen content (mg) was converted to protein units using the linear calibration curve generated from standards (Vitrogen 100; Angiotech Biomaterials, Palo Alto, CA, USA) and was normalized to the total protein (mg) of each sample.
Western blotting
Total protein was extracted from cells or tissues and its concentration was determined using a bicinchoninic acid kit. The samples were boiled for 5 min and loaded at 80 μg per lane. The Western blotting procedures were as previously described . GAPDH was used as the internal control. The antibody sources were as follows: anti-TGFBR3, anti-phosphop38, anti-phospho-ERK1/2, anti-phospho-JNK, anti-p38, anti-ERK1/2, anti-JNK (1:1000 dilution; Cell Signalling Technology, Beverly, MA, USA), anti-GIPC1 (1:150 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-GAPDH (1:500 dilution; Research Diagnostics, Concord, MA, USA).
Co-immunoprecipitation
For co-immunoprecipitation (co-IP), cells or tissues were lysed in RIPA buffer (Beyotime, Shanghai, China) and then centrifuged at 12 000× g for 15 min. The supernatant was collected and aliquoted into three parts for control input, primary antibody and control IgG. The primary antibody and IgG were incubated with protein A/G agarose beads at 4°C overnight on a shaker. After the incubation, the samples were centrifuged at 3000× g for 5 min, and the beads were collected and washed with PBS three times. The appropriate amount of loading buffer was added to the beads, which were boiled for 5 min and then centrifuged at 12 000× g for 5 min to dissociate the proteins from the beads. The IP products were subsequently analysed using Western blotting.
Echocardiographic measurement
To test left ventricular function, transthoracic echocardiography was performed using an ultrasound machine (Vivid 7 GE Medical; GE Healthcare, Horten, Norway) with a 10 MHz phase-array transducer as previously described (Pan et al., 2012) .
Data analysis
The data are presented as the means ± SEM and were processed with GraphPad Prism 5.0. One-way ANOVA with Bonferroni's post hoc test was used for multiple comparisons. A two-tailed value of P < 0.05 was considered statistically significant.
Results
Simvastatin attenuates myocardial fibrosis and improves cardiac function in mice after MI induction
First, to detect the effect of simvastatin on cardiac fibrosis, mice were pretreated with simvastatin or normal saline for 7 days and were subjected to LAD ligation for 1 week or 4 weeks. The tissues of the border zone of the infarct were then subjected to collagen staining and electron microscopy to determine the effects of simvastatin on collagen production and fibroblast activity respectively.
Masson staining showed that 7 day infarction induced massive collagen production and that simvastatin pretreatment alleviated the MI-induced collagen deposition by 67% (Figure 1) . Similar results were observed in electron micrographs. In the control groups, the myocardium presented an orderly myofibril distribution, collagen in myocardial interval was rarely seen, and fibroblasts were in a quiescent state. In the MI groups, cardiomyocytes presented fractured mitochondrial cristae, disorderly sarcomere structures and an interstitial space filled with massive fasciculate collagen and active fibroblasts. In the simvastatin-treated groups, less collagen was deposited, and fibroblasts were quiescent (Figure 1) . The lower degree of infarction injury in simvastatin-treated mice indicated that simvastatin partly protected the heart from the MI insult, which was manifested as a decrease in interstitial collagen deposition and fibroblast activity. Table 1 presents the echocardiographic parameters evaluated in the three groups of mice after 4 week MI. The increased interventricular septal thickness in diastole (IVSd), the interventricular septal thickness in systole (IVSs), the left ventricular internal dimension diastole (LVIDd) and the left ventricular internal diameter in systole (LVIDs) with decreased fractional shortening (FS) and ejection fraction (EF) values confirmed the myocardial fibrosis. Simvastatin-treated mice exhibited reversal of FS and EF. The changes in heart function indicate that simvastatin may regulate cardiac fibrosis and the unchanged parameters are consistent with the reports that simvastatin has no effect on hypertrophy (Hermida et al., 2013) .
Simvastatin up-regulates TGFBR3 and suppresses ERK1/2 and JNK pathways in vivo
TGFBR3, a glycosaminoglycan transmembrane receptor, inhibits collagen production by reducing TGF-β1 signalling activity and is closely involved in the development of cardiac fibrosis (Liang et al., 2012) . We further noted that TGFBR3 was involved in MI injury because of the decreased level of TGFBR3 after 24 h of MI. However, TGFBR3 was up-regulated nearly 1.33-fold in MI mice with simvastatin pretreatment (Figure 2A ).
Figure 1
Simvastatin reduces cardiac fibrosis in ventricular tissue of mice following MI. Mice were pretreated with simvastatin (ST; 0.5 mg·g −1 ·day −1 ) for 7 days and the LAD ligated for 1 week. Collagen deposition and ultrastructure were determined by Masson staining and electron microscopy (EM). Microscope images show a thicker collagen fibre pattern (blue) in the MI groups than in the control groups, and simvastatin reduced this intense collagen deposition. Representative images from electron microscopy: (i) control: black arrow indicates normal cardiac fibroblasts; (ii) MI: excessive proliferation of cardiac fibroblasts and collagen deposition (blue); (iii) simvastatin-treated: quiescent cardiac fibroblasts and less collagen deposition. Ctrl, control; ST, simvastatin; EM, electron microscopy. *P < 0.05 versus control group; #P < 0.05 versus MI group. n = 6.
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Notably, the ERK1/2 pathway is involved in the expression of collagen genes in human peritoneal mesothelial cells and is involved in collagen type I transcriptional activation of fibroblasts derived from aged murine hearts. The specific ERK1/2 inhibitor PD98059 suppresses collagen I mRNA expression after TGF-β1 treatment in human peritoneal mesothelial cells (Hung et al., 2001a) . Additionally, JNK phosphorylation is associated with augmented proliferation and collagen production in renal fibroblasts . In our experiments, the activities of the ERK1/2 and JNK pathways correlated closely with the severity of cardiac fibrosis, and MI up-regulated ERK1/2 and JNK phosphorylation, whereas simvastatin depressed this increased phosphorylation ( Figure 2B and D) . MI also activated the p38 pathway, but this pathway was not altered significantly after simvastatin ( Figure 2C ).
The inhibitory effects of simvastatin on cell proliferation and collagen content are mediated by elevated TGFBR3 expression in neonatal mouse cardiac fibroblasts (NMCFs)
TGFBR3 appears to function as an inhibitor of cardiac fibrosis via several mechanisms (Ezquerro et al., 2003; Hermida et al., 2009) . To test whether raised levels of TGFBR3 were critical to simvastatin-induced anti-fibrosis in infarcted heart, we treated NMCFs with various doses of simvastatin for 24 h. TGFBR3 was then detected using Western blotting ( Figure 3A) , which revealed that TGFBR3 expression increased in a dose-dependent manner. The TGFBR3 level was increased to twice that of the control group by 5 μM simvastatin and to 2.5-fold by 10 μM simvastatin. The effect of simvastatin on TGFBR3 expression indicated that TGFBR3 was involved in the signalling pathway that underlies simvastatin's anti-fibrotic action.
Given these results, we used siRNA to block TGFBR3 expression in NMCFs. The degree of TGFBR3 knock-down is shown in Figure 3B . As Figure 3C shows, the increase in total collagen content induced by FBS stimulation was prevented by 10 μM simvastatin. Strikingly, TGFBR3 knock-down reversed this inhibition of collagen by simvastatin.
Fibroblast over-proliferation is a characteristic finding in cardiac fibrosis and contributes greatly to its pathogenesis. Therefore, fibroblast proliferation reflects cardiac fibrosis injury. We measured NMCF proliferation via MTT assay and found that, as shown in Figure 3D , FBS promoted overproliferation whereas simvastatin eliminated this effect. As expected, this suppression of cell proliferation was abolished by TGFBR3 knock-down. These results confirmed that simvastatin inhibited NMCF proliferation and that TGFBR3 was an important factor in the regulation of fibroblast proliferation by simvastatin.
Knock-down of TGFBR3 abolishes the inhibitory role of simvastatin in regulating ERK1/2 and JNK activation in NMCFs
To detect whether ERK1/2 or JNK signalling acts downstream of TGFBR3, cells transfected with TGFBR3 siRNA or negative control siRNA were treated with simvastatin or FBS. Enhanced ERK1/2 phosphorylation was observed in the FBS group, which was further increased by TGFBR3 siRNA ( Figure 4A ). Furthermore, simvastatin partly inhibited ERK1/2 phosphorylation whereas TGFBR3 knock-down cancelled the inhibitory effect of simvastatin on ERK1/2 signalling ( Figure 4C ). Similar results were observed in JNK signalling ( Figure 4B and D) . Thus, the decreased activation of the ERK1/2 and JNK pathways induced by simvastatin was dependent on the presence of TGFBR3.
TGFBR3 inhibits ERK1/2 and JNK signalling by interacting with GIPC
The PDZ-protein GIPC interacts with TGFBR3 to stabilize TGFBR3 at the cell surface and enhance TGF-β signalling (Blobe et al., 2001; Sanchez et al., 2011) . Moreover, regulation of breast cancer progression and epithelial-mesenchymal transformation requires TGFBR3 interaction with GIPC (Lee et al., 2010; Sanchez et al., 2011; Townsend et al., 2012) . However, the mechanism by which TGFBR3-GIPC mediates cell activity is poorly understood. Interestingly, investigations regarding the association between GIPC and the ERK1/2 pathway have indicated a role for GIPC in a TGFBR3-ERK1/2 pathway (Hu et al., 2003) . To confirm the interaction between TGFBR3 and GIPC, we performed co-IP ( Figure 5A ). NMCFs were co-transfected with pc-DNA3.1-mTGFBR3 plasmid and GIPC siRNA for 48 h. The transfection efficiencies are shown in Figure 5B and C. Western blotting revealed that TGFBR3 overexpression decreased ERK1/2 and JNK pathway activities by 60%, whereas treatment with the siRNA for GIPC restored the activities to control levels ( Figure 5D and E). These results suggest that the interaction between TGFBR3 and GIPC was essential for the activation of the ERK1/2 and JNK pathways.
Lentivirus-mediated TGFBR3 silencing reverses anti-fibrotic effect by simvastatin in vivo
To determine the role of TGFBR3 in the modulation of cardiac fibrosis by simvastatin in vivo, Lenti-shTR3 was injected into the myocardium to knock-down TGFBR3 in cardiac fibroblasts. Mice were then treated with simvastatin and the LAD was ligated. The border tissues of the resulting infarct were examined. Knock-down of TGFBR3 in cardiac fibroblasts was confirmed by Western blotting and
Figure 2
Simvastatin alters TGFBR3 expression and MAPK phosphorylation in vivo. Mice were pretreated with simvastatin (ST; 0.5 mg·g −1 ·day −1 ) for 7 days and the LAD ligated for 1 day. TGFBR3(A), ERK1/2 and p-ERK1/2 (B), p38 and p-p38 (C) and JNK and p-JNK (D) were measured using Western blotting. Data are presented relative to control (Ctrl) and are shown as the means ± SEM. *P < 0.05 versus control group; #P < 0.05 versus MI group. n = 6. BJP F Sun et al. Information Fig. S1 ). Knock-down of TGFBR3 also reduced the anti-fibrotic effect of simvastatin in the infarcted heart. Masson staining exhibited up-regulated collagen staining in Lenti-shTR3 group compared with Lenti-shNC group after 7 day MI. Electron micrographs showed more serious injury of MI in the shTGFBR3 group, with marked deposits of fasciculate collagen and hypertrophied and activated fibroblasts ( Figure 6A ). Heart function evaluated by echocardiography showed that FS and EF were lower in Lenti-shTR3 group after 7 days of MI ( Figure 6B ), indicating the critical contribution of TGFBR3 to the improvement in heart function after simvastatin. These results suggest that TGFBR3 is a critical component of the procesess whereby simvastatin protects against cardiac fibrosis, decreases collagen deposition and inhibits fibroblast activity.
fluorescence (Supporting
Consistent with the results in vitro, the interaction between TGFBR3 and GIPC in vivo was confirmed by co-IP ( Figure 6C ). Furthermore, border tissue exhibited more activated ERK1/2 and JNK pathway in Lenti-shTR3 group, but the p38 pathway was not altered significantly ( Figure 6D-F) . These results further indicate that the anti-fibrotic role of TGFBR3 in heart is mediated by GIPC to regulate ERK1/2 and JNK signalling pathways.
Figure 3
Identification of TGFBR3 as a novel target of the inhibitory effects of simvastatin on collagen content and cell proliferation. (A) Cultured NMCFs were incubated for 2 h with 1, 5 or 10 μM simvastatin (ST). (B, C, D) NMCFs were transfected with TGFBR3 siRNA for 48 h and then incubated for 2 h with 10 μM simvastatin or 20% FBS for 2 h. Collagen production was assayed with a Sircol Collagen Assay kit (C) and proliferation of NMCFs by MTT assay (D). Western blotting was used to determine TGFBR3 expression. Data are shown as the means ± SEM. *P < 0.05 versus control group; §P < 0.05 versus FBS treatment alone; †P < 0.05 versus FBS+ST+si-NC. n = 5.
Discussion and conclusions
The current work provides strong evidence that TGFBR3 stimulated by simvastatin down-regulated the post-infarct accumulation of interstitial collagen and inhibited cardiac fibroblast activity, by interacting with GIPC to mediate MAPK (ERK1/2 and JNK) signalling (Figure 7) . Thus, our current findings identified TGFBR3 as a worthwhile target in the anti-fibrotic effects of simvastatin in the heart. Cardiac fibrosis that is caused by coronary artery stenosisinduced ischaemia and hypoxia triggers increases in heart volume and weight, along with fibroplasia and even transmural scarring, and ultimately causes arrhythmia and heart failure (Kong et al., 2012) . Pathological changes after MI due to occlusion of the LAD, show a long-term progression. In the rat MI model, for instance, fibroblast proliferation occurs at day 4 after MI and cardiac fibrosis is detected 7 days after MI. By day 28, the ischaemic heart develops significant
Figure 4
Silencing TGFBR3 restricts down-regulation of ERK1/2 and JNK phosphorylation by simvastatin. (A and B) NMFCs were transfected with TGFBR3 siRNA for 48 h and incubated for 2 h with 20% FBS. (C and D) NMCFs were transfected with TGFBR3 siRNA for 48 h, then incubated for 2 h with 10 μM simvastatin (ST) or with 20% FBS for 2 h. ERK1/2 and JNK phosphorylation was quantified using Western blotting. Data are shown as the means ± SEM. *P < 0.05 versus control group; §P < 0.05 versus FBS treatment alone; #P < 0.05 versus FBS+ si-NC; †P < 0.05 versus FBS+ST+si-NC. n = 4.
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compensatory hypertrophy and, eventually, heart failure (Backlund et al., 2004; Krzeminski et al., 2008; Pan et al., 2012) .
Our investigation showed that simvastatin prevented the development of cardiac fibrosis by decreasing collagen production and fibroblast proliferation, consistent with previous reports. Rosuvastatin ameliorates chronic heart failure induced by ischaemic heart disease in humans (Cleland et al., 2009; McMurray et al., 2009; Askevold et al., 2013) . Compared with placebo, simvastatin decreased left ventricular mass, interventricular septal thickness and posterior wall thickness in a β-myosin heavy chain-Q transgenic rabbit model of human hypertrophic cardiomyopathy (Patel et al., 2001) . These findings agree with our observations from the treatment of mice with oral simvastatin. In the present study, after 7 or 28 days, our model of MI induced a significant loss of heart function, confirming the success of LAD ligation, and treatment with simvastatin decreased the cardiac fibrosis and improved cardiac dysfunction. The impaired FS and EF at day 28 demonstrate poor heart function and these parameters were particularly improved by simvastatin. Simvastatin, however, did not inhibit myocardial hypertrophy as seen from the unchanged IVSd, IVSs, LVIDd and LVIDs, which is consistent with earlier results showing no effect of statins on
Figure 5
TGFBR3 interaction with GIPC is critical to the down-regulation of ERK1/2 and JNK signalling by simvastatin. (A) TGFBR3-GIPC complexes were measured by co-IP. (B-E) NMCFs were co-transfected with pc-DNA3.1-m TGFBR3 plasmid and GIPC1 siRNA for 48 h. TGFBR3 and GIPC expression and ERK1/2 and JNK phosphorylation were quantified using Western blot. Data are shown as the means ± SEM. *P < 0.05 versus control group; #P < 0.05 versus TGFBR3+si-NC. n = 4. cardiomyocyte hypertrophy after 7 day MI (Hermida et al., 2013) . The present study combined with earlier studies confirmed that the protective effect of simvastatin is not through prevention of cardiomyocyte hypertrophy, but due to the amelioration of cardiac fibrosis (Shiroshita-Takeshita et al., 2007; Hermida et al., 2013) .
Furthermore, in dogs subjected to ventricular tachypacing to induce CHF, simvastatin suppressed proliferation of atrial fibroblasts (Shiroshita-Takeshita et al., 2007) . Additionally, statins reduced pro-collagen type I production, α-smooth muscle actin expression and fibroblast migration by activating AMP-activated protein kinase in a mouse model of the metabolic syndrome (Hermida et al., 2013) . These findings are compatible with our observations that simvastatin suppresses MI-induced collagen production and fibroblast activity. Together, these results suggest that statins can be effective against myocardial remodelling. However, more investigations are needed to fully explain the mechanism(s) of the actions of statins.
We have focused on the mechanism of the anti-fibrotic effects of statins. After a 1 day MI injury, TGFBR3 expression declined, which was reversed by simvastatin, and simvastatin attenuated the activated ERK1/2 and JNK signalling. Atorvastatin down-regulates endoglin expression via PI-3 kinase, Akt and Smad3 phosphorylation (Shyu et al., 2010) . Endoglin is the related TGF-β superfamily co-receptor that shares a limited amino acid sequence identity with TGFBR3 and is expressed in some cell types which have little or no TGFBR3 expression, to compensate for its absence (Letamendia et al., 1998; Gatza et al., 2010) . Interestingly, in cardiac fibroblasts, a synthetic peptide from TGFBR3, P144, reduced TGF-β1-dependent signalling and collagen I synthesis (Hermida et al., 2009 ) and also reduced liver fibrogenesis in rats with CCl 4 liver injury (Ezquerro et al., 2003) . Furthermore, TGFBR3 overexpression inhibits miR-21 and collagen production in NMFCs (Liang et al., 2012) . All this evidence raised the possibility that TGFBR3 was the target of simvastatin in its antifibrotic actions. Our results showed that TGFBR3 knock-down prevented the down-regulation of collagen production and cell proliferation induced by simvastatin, confirming our hypothesis.
In addition to TGFBR3 expression, ERK1/2 and JNK signalling was activated after MI, whereas simvastatin reduced the levels of activated ERK1/2 and JNK. Interestingly, the MAPK pathway associated with the development of cardiac fibrosis has been reported in several studies (Ponticos et al., 2009; Lagares et al., 2010; Jang et al., 2013) . In human peritoneal mesothelial cells and fibroblasts derived from aged murine hearts, the ERK1/2 pathway alters collagen production and cell proliferation (Hung et al., 2001a,b) . Inhibiting ERK1/2 or JNK showed positive effects on cardiac contractility and decreased the area of fibrotic tissue and progression of myocardial fibrosis in cardiomyopathy caused by mutation in the lamin A/C gene (Wu et al., 2011) . Furthermore, suppression of JNK signalling reduced the increase in the mRNA levels of profibrogenic genes by aristolochic acid and reduced fibroblast proliferation in kidneys after injury (Yang et al., 2010) . Thus, research on the utility of targeting ERK1/2 and JNK to treat cardiac fibrosis seems worthwhile, but few experiments have been performed. Notably, simvastatin attenuated ERK1/2 activation caused by hyaluronan-mediated motility (Wang et al., 2014) . Additionally, several statin-treated cells show decreased ERK1/2 activity (Nemoto et al., 2012; Chen et al., 2013; Qi et al., 2013) . Inhibition of TNF-α-induced
Figure 7
A diagram of the involvement of TGFBR3 in the inhibition by simvastatin of cardiac fibrosis induced by MI. Simvastatin repairs the dysfunctional TGFBR3 (TRIII) signalling induced by MI. TGFBR3 further interacts with GIPC, down-regulates ERK1/2 and JNK signalling pathways and consequently reduces cardiac fibrosis. membrane localization of Ras and RhoA by simvastatin leads to reduced phosphorylation of ERK1/2 and JNK in mouse myoblast C2C12 cells (Yamashita et al., 2008) . Therefore, we focused on the mechanism by which simvastatin regulates MAPK pathways.
We hypothesized that simvastatin down-regulated MAPK signalling by inducing TGFBR3 expression. Our results showed that simvastatin abolished ERK1/2 and JNK activation, which was reversed by silencing of TGFBR3 in vitro. Furthermore, we silenced TGFBR3 by lentivirus in vivo and confirmed that TGFBR3 played a critical role in the improvement of heart function, decreased collagen deposition and reduced activation of the MAPK pathway, induced by simvastatin. As a consequence, TGFBR3 was identified as the target of simvastatin in its regulation of the MAPK pathway.
The next challenge was to determine how TGFBR3 regulates ERK1/2 and JNK phosphorylation. TGFBR3 is divided into a cytoplasmic domain and an extracellular domain by the cell membrane (Gatza et al., 2010) . It mediates cell activities, including migration, apoptosis and invasion, through its cytoplasmic domain's interactions with specific proteins (You et al., 2007) . GIPC's interaction with the cytoplasmic domain of TGFBR3 via the TGFBR3 class I PDZ-binding domain stabilizes TGFBR3 levels and inhibits the TGF-β signalling that mediates cell migration and invasion (Blobe et al., 2001; Lee et al., 2010; Sanchez et al., 2011; Townsend et al., 2012) . In the present study, we confirmed the interaction between TGFBR3 and GIPC. Knock-down of GIPC reversed the downregulation of the ERK1/2 and JNK pathways by TGFBR3 overexpression. Thus, TGFBR3 affects the ERK1/2 and JNK pathways, after interaction with GIPC. Although knockdown of GIPC blocked the effects of TGFBR3 on MAPK signalling, the present study does not explain how GIPC regulates ERK1/2 and JNK pathway activation. Hu et al. (2003) demonstrated that GIPC directly interacts with β 1-adrenoceptors to regulate ERK1/2 activation mediated by these receptors, which may resemble the regulation of the ERK1/2 pathway by GIPC. Most notably, although we identified simvastatin as an anti-fibrotic agent in the heart by its targeting of TGFBR3, no upstream regulator of simvastatininduced TGFBR3 expression has been identified. Our recent study showed that miR-21, a critical regulator of cardiac fibrosis development, directly down-regulated TGFBR3 and formed a positive feedback loop with TGFBR3 in cardiac fibrosis progression (Liang et al., 2012) . Therefore, it is worthwhile to examine whether simvastatin affects miR-21-TGFBR3 signalling in our model. In summary, this study provides good experimental evidence that statins prevent cardiac fibrosis and that the TGFBR3/GIPC interaction is involved in statin-induced inhibition of the activation of ERK1/2 and JNK signalling. These results aid our understanding of the mechanisms by which statins protect heart function, and they reveal modulation of TGFBR3 expression in cardiac fibroblasts as a potential approach for the prevention or treatment of cardiac fibrosis.
